Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (193)	11/26/1997 12:41:00 AM
From: Robert Cohen	Respond to of 1494

My basis for investing in NTII has alwlays been Memantine. I liked it enough to buy at $4.00, add more at $3.00 and more at $1.75 last July. It seems to me that NTII's limited funds are sufficient to last through phase II results for Memantine's treatment of neruropathic pain. The Company on Nov, 4 stated that the patient enrollment had been completed for the eight week study. Therefore results should be had by January. If you believe that memantine has a reasonable chance of success, 1.75 seems like a bargain price to pay for a hopeful New Year's celebration. I bought more today. At this Thanksgiving time, let's remember its only money we're talking about. Let's hug a loved one, hug a stranger and count are blessings for our health, our families, friends and communities, and the fact that the wolf is sufficiently away from our door, that we can even discuss whether we should invest in NTII. Happy Thanksgiving to all.